SS-31 (elamipretide) has real clinical-trial data behind its side-effect profile, which sets it apart from most research peptides. Across its program the most consistent reactions were injection-site reactions, reflecting its daily subcutaneous route.[1][2]
Reviewed for accuracy · Last reviewed July 7, 2026Because its approval is narrow (Barth syndrome) and recent, and several of its larger trials did not meet primary efficacy endpoints, its adverse-effect profile is best understood within the specific studied populations rather than as a broadly characterized safety record. Research use outside those settings is not well studied, and independently sourced material adds product-quality uncertainty on top of any biological effect.
Injection-site reactions are the effect most often reported, and rotating sites is the usual practical step. Anything suggesting an allergic reaction is a reason to seek medical attention rather than continue.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.